At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
Levosimendan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Prophylactic Effect of Levosimendan in Reducting Acute Kidney Injury Postoperatively in Pediatric Patients Undergoing Corrective Heart Surgery
In Brief
A Phase 2 clinical trial evaluating Levosimendan and Milrinone for Congenital Heart Defects. Completed, enrolled 72 participants across 2 sites in 2 countries.
Detailed Summary
The aim of the study is to assess the ability of Levosimendan to reduce the postoperative acute kidney injury in pediatric patients undergoing surgery for congenital heart disease (CHDs).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCongenital Heart Defects
CountriesFinland, Sweden
CollaboratorsHelsinki University Central Hospital
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartOct 2014
Primary CompletionApr 2017
TodayJul 2026
First PostedSep 5, 2014
Enrollment StartOct 15, 2014
Primary CompletionApr 25, 2017
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 11.8 years ago
Interventions
Levosimendandrug
The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
Milrinonedrug
The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.